加拿大卫生部报告肿瘤药物的生活质量

IF 2 Q3 HEALTH POLICY & SERVICES

Journal of Cancer Policy Pub Date : 2025-05-03 DOI:10.1016/j.jcpo.2025.100594

Joel Lexchin

{"title":"加拿大卫生部报告肿瘤药物的生活质量","authors":"Joel Lexchin","doi":"10.1016/j.jcpo.2025.100594","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Quality of Life (QoL) information regarding oncology drugs is important for patients, especially those who are receiving treatment for symptom control and not for curative purposes. Health Canada guidance documents do not describe how QoL information should be reported. This study examines how Health Canada reports QoL in documents regarding the decision to approve and indications for new oncology drugs.</div></div><div><h3>Methods</h3><div>A list of all oncology drugs approved by Health Canada from 2019 to 2023 was created using a Health Canada website. Documents describing why a decision was made to approve a new drug and how QoL influenced indications for the drug were searched for the term “Quality of Life” and relevant passages were recorded verbatim.</div></div><div><h3>Results</h3><div>Health Canada approved 60 oncology drugs. QoL only influenced approval in 1 case and was only mentioned in a drug’s indication in 3 cases.</div></div><div><h3>Conclusion</h3><div>Health Canada only reports QoL information very infrequently for oncology drugs.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"44 ","pages":"Article 100594"},"PeriodicalIF":2.0000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Health Canada reporting on quality of life for oncology drugs\",\"authors\":\"Joel Lexchin\",\"doi\":\"10.1016/j.jcpo.2025.100594\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Quality of Life (QoL) information regarding oncology drugs is important for patients, especially those who are receiving treatment for symptom control and not for curative purposes. Health Canada guidance documents do not describe how QoL information should be reported. This study examines how Health Canada reports QoL in documents regarding the decision to approve and indications for new oncology drugs.</div></div><div><h3>Methods</h3><div>A list of all oncology drugs approved by Health Canada from 2019 to 2023 was created using a Health Canada website. Documents describing why a decision was made to approve a new drug and how QoL influenced indications for the drug were searched for the term “Quality of Life” and relevant passages were recorded verbatim.</div></div><div><h3>Results</h3><div>Health Canada approved 60 oncology drugs. QoL only influenced approval in 1 case and was only mentioned in a drug’s indication in 3 cases.</div></div><div><h3>Conclusion</h3><div>Health Canada only reports QoL information very infrequently for oncology drugs.</div></div>\",\"PeriodicalId\":38212,\"journal\":{\"name\":\"Journal of Cancer Policy\",\"volume\":\"44 \",\"pages\":\"Article 100594\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213538325000384\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH POLICY & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538325000384","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

关于肿瘤药物的生活质量（QoL）信息对患者很重要，特别是那些接受症状控制而非治疗目的治疗的患者。加拿大卫生部的指导文件没有说明应如何报告生活质量信息。本研究考察了加拿大卫生部如何在有关批准新肿瘤药物的决定和适应症的文件中报告生活质量。方法使用加拿大卫生部网站创建了2019年至2023年加拿大卫生部批准的所有肿瘤药物清单。用“生活质量”一词搜索描述为何决定批准一种新药以及生活质量如何影响该药物适应症的文件，并逐字记录相关段落。结果加拿大卫生部批准了60种肿瘤药物。生活质量仅影响1例的批准，仅在3例的适应症中被提及。结论加拿大卫生部很少报告肿瘤药物的生活质量信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Health Canada reporting on quality of life for oncology drugs

Introduction

Quality of Life (QoL) information regarding oncology drugs is important for patients, especially those who are receiving treatment for symptom control and not for curative purposes. Health Canada guidance documents do not describe how QoL information should be reported. This study examines how Health Canada reports QoL in documents regarding the decision to approve and indications for new oncology drugs.

Methods

A list of all oncology drugs approved by Health Canada from 2019 to 2023 was created using a Health Canada website. Documents describing why a decision was made to approve a new drug and how QoL influenced indications for the drug were searched for the term “Quality of Life” and relevant passages were recorded verbatim.